TAK1 signaling is a potential therapeutic target for pathological angiogenesis.

导出 LinkOut

翻译打印收藏纠错

第一作者： Linxin,Zhu

第一单位： Menzies Institute for Medical Research, University of Tasmania, 17 Liverpool Street, Hobart, TAS, 7000, Australia.

作者： Linxin,Zhu ^[1] ; Suraj,Lama ^[2] ; Leilei,Tu ^[1] ; Gregory J,Dusting ^[2] ; Jiang-Hui,Wang ^[3] ; Guei-Sheung,Liu ^[4]

作者单位： Menzies Institute for Medical Research, University of Tasmania, 17 Liverpool Street, Hobart, TAS, 7000, Australia. ^[1] Department of Ophthalmology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China. ^[2] Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, VIC, Australia. ^[3] Ophthalmology, Department of Surgery, University of Melbourne, East Melbourne, VIC, Australia. ^[4] Menzies Institute for Medical Research, University of Tasmania, 17 Liverpool Street, Hobart, TAS, 7000, Australia. rickliu0817@gmail.com. ^[5] Ophthalmology, Department of Surgery, University of Melbourne, East Melbourne, VIC, Australia. rickliu0817@gmail.com. ^[6] Aier Eye Institute, Changsha, Hunan, China. rickliu0817@gmail.com. ^[7]

关键词 Angiogenesis Hypoxia Inflammation Oxidative stress Transforming growth factor β activated kinase 1

主题词动物(Animals);药物释放系统(Drug Delivery Systems);人类(Humans);MAP激酶激酶激酶类(MAP Kinase Kinase Kinases);新生血管化, 病理性(Neovascularization, Pathologic);信号传导(Signal Transduction)

DOI 10.1007/s10456-021-09787-5

PMID 33973075

发布时间 2022-09-10

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交